Abstract
Sepsis is defined as a life-threatening organ dysfunction, which is caused by a dysregulated host response to infection. The composition of the intestinal microbiota is significantly different between patients with sepsis and healthy individuals. Intestinal microbial imbalance plays an important role in the occurrence and development of sepsis. Our review mainly introduces the mechanism of intestinal microbiota involvement in sepsis, the effects of microbiota dysbiosis on the damage of multiple organs and concisely discusses the prospects for microbe-specific treatment of sepsis in the future.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
1 Introduction
Sepsis is the major cause of morbidity and mortality and is a major public health problem worldwide [1]. Sepsis accounts for nearly 26% of all deaths worldwide, with more than 20 deaths per minute [2]. It is defined as a dysregulation of the host response to infection leading to life-threatening organ dysfunction [3].
The intestinal microbiota is a huge and complex ecosystem, accounting for approximately 80% of the total flora. The intestinal flora is mainly composed of Firmicutes and Bacteroidota [4,5,6] in healthy volunteers. It is also known as the second genome and has a significant impact on human health [7]. The intestinal microbiota is also considered an important part of the intestinal barrier [8]. An imbalance of the intestinal flora may lead to bacterial translocation by increasing intestinal permeability and inducing mucosal immune dysfunction [9]. Microbiota dysbiosis can lead to various diseases, including diabetes and obesity [10,11,12]. Recently, it has also been considered an important factor for increased susceptibility to sepsis [13]. In a single-center controlled case study, 20 classifications of gut microbiota were used as markers for the diagnosis of sepsis, and the receiver operating characteristic score reached 81.25% [14]. It has also been reported that the gut microbiota may be an active participant in the development of sepsis [15, 16]. Therefore, targeted therapy of gut microbiota may be a promising strategy for sepsis. Here, we discussed the role of intestinal flora in the development of sepsis, and summarized the latest progress in the field of targeted treatment of sepsis.
2 Microbiota Disorder Related to Sepsis
In sepsis, factors such as hypoxic injury, inflammation, intestinal motility dysfunction, destruction of epithelial cell integrity can change the composition and proportion of intestinal microbiota [15, 17]. Some harmful bacteria such as Vibrio cholerae and Trichinella spiralis [18] could induce mucin degradation and inhibit mucus production. However, Lactobacillus spp could stimulate mucin3 and mucin2 production and secretion [19, 20], Akkermansia muciniphila could restore mucus growth and increase the number of goblet cells [21]. The microbial metabolites of short-chain fatty acids (SCFAs) also could stimulate mucin2 expression, increasing mucus secretion [22]. Intestinal micro-ecological collapse may occur in sepsis, and the dominant genus changes from common symbiotic bacteria to pathogenic genus [23]. The function to maintain healthy bacteria, such as Faeculus, Prevotella, Verrucobacterium, and Lauterella, also decreases [24]. The intestinal flora of septic shock patients is characterized by low population diversity and high degree of individualization associated with excessive reproduction of single genus [25, 26]. Significant changes in microbiota may be related to the progression of sepsis [27]. Studies have showed that the gut microbiota is involved in the pathogenesis of late onset sepsis (LOS) and is the main risk factor for LOS [28, 29]. Du et al. found the microbiota dysbiosis was associated with increased mortality, and the gut microbiota can be used as a prognostic marker of sepsis [30].
Under stress conditions, the production of opioids can reduce intestinal peristalsis, enhance the virulence of Pseudomonas aeruginosa, and promote the overgrowth of intestinal pathogenic bacteria [31,32,33]. A study of 1,265 intensive care unit (ICU) patients [34] found that more than 75% patients received antibiotic treatment every day, which usually comprised two or more antibiotics. Many broad-spectrum antibiotics inhibit or kill the dominant bacteria, which causes increased colonization by conditional pathogens and fungi, results in opportunistic or secondary infections, and aggravates intestinal microecological imbalance [35]. Broad-spectrum antibiotics also increase the risk of Clostridium difficile infection [36, 37], as well as the incidence of antibiotic-related diarrhea [38].
Parenteral nutrition damages the inherent mucosal immune function, leads to changes in the intestinal flora, reduces the expression of antibacterial protein from the intestinal Paneth cells and the bactericidal activity of mucosal secretions, and increases the sensitivity of intestinal invasion of Escherichia coli [39]. It is related to the increase of Treg and CD8 + T cells, reducing the total number of CD4 + T cells [40]. It also affects the function of intestinal-associated lymphoid tissue, and increases the expression of interleukin (IL)-4, IL-10 and immunoglobulin (Ig)A mRNA [41]. Significant changes in intestinal metabolomic components and increased intestinal permeability were observed after parenteral nutrition [42]. Long-term parenteral nutrition has a significant adverse effect on the levels of Lactobacilli and Bifidobacterium in preterm infants [43]. A recent meta-analysis suggests that parenteral nutrition has a higher abundance of Proteobacteria, the lower Firmicutes, Bacteroides and microbial diversity than enteral nutrition [44].
Intravenous infusion resulted in a dose-dependent increase in Bacteroides, decreased recombinant sodium/glucose cotransporter 1 (SGLT1) and Caspase3 levels, and arrested a transient increase in opportunistic pathogens, suggesting that crystal resuscitation may be beneficial to intestinal health [45]. It also affected the intestinal microbiome beta diversity and reduced the impact of bleeding on intestinal ecological imbalance [46]. Yang et al. found that microbiota led to the development of inflammation and intestinal mucosal high permeability after resuscitation [47]. However, Muraoka et al. found that resuscitation aggravated the loss of microbiota diversity and the danger of intestinal flora imbalance, which may be due to the high permeability of blood vessels and supplying a growth matrix for bacteria [48].
A retrospective analysis of 831 patients with bloodstream infections showed that hemodialysis is an independent risk factor for bloodstream infections [49]. The microbial abundance and diversity in hemodialysis patients showed a downward trend [50], and the altered intestinal bacteria may impact the prognosis of patients [51].
In addition, alkaline phosphatase in the normal intestine can catalyze the dephosphorylation reaction of lipopolysaccharide and weaken the stimulatory effect of lipopolysaccharide on Toll-like receptor 4 (TLR4) [52]. In sepsis, the phosphate necessary for the proliferation and growth of bacteria is reduced, which changes the type and virulence of intestinal microorganisms [53]. Pseudomonas aeruginosa appears and proliferates, in addition to secreting agglutination of plasminogen activator inhibitors or adhesin [54], and destroying the intestinal epithelial barrier, while Candida albicans transforms into a lethal phenotype [55].
3 Interaction Between Intestinal Microbiota and Systemic Immunity
The intestinal flora not only plays an important role in innate [56] and intestinal mucosal immunity [57, 58], but also affects intestinal microcirculation through inflammation and vascular reaction [59]. Studies have observed that IgA-secreting cells [60] and CD4+ T cells [61] were significantly reduced in germ-free mice. The destruction of the balanced intestine could cause immune system responses [62], leading to inflammatory reactions and ultimately destroying the mucosal barrier [63]. The intestinal flora affects the systemic immune response by regulating several key pathways, including the production of SCFAs [64], oral immune tolerance [65], control of inflammatory T cell populations, and expansion and differentiation of extraintestinal T cells [66, 67]. Disordered intestinal flora can induce a decrease in the number and differentiation of dendritic cells [68], suppress T cell immune responses [69], and increase susceptibility to pathogenic microorganisms in sepsis [70]. In addition, flora dysbiosis can induce the macrophages to differentiate into the M1 type [71] and release tumor necrosis factor-α (TNF-α), IL-1 [72], and IL-6 [73], which aggravate the inflammatory reaction in sepsis (Fig. 1).
4 Intestinal Microbiota is a Main Source of Respiratory Flora
Intestinal flora could provide extensive protection against respiratory infections to a certain extent. Mice with reduced intestinal flora demonstrate an impaired immune response to bacterial or viral infection in the respiratory tract [74]. A recent study confirmed that the imbalance in intestinal flora could activate the TLR4/NF-κB pathway, thereby upregulating lung tissue inflammation (Fig. 1). It could be a major reason to explain why the lung is often the first organ to be injured after bacterial translocation [75].
The prevalence of intestinal flora in the bronchoalveolar lavage fluid of patients with sepsis is high and is related to systematic inflammation. The lung microbes recovered in septic mice are mostly similar to intestinal flora, suggesting that the lower digestive tract could be the main source of lung flora [73]. Translocation of the intestinal microbiota seems to be related to the development of acute respiratory distress syndrome (ARDS). Dickson et al. [75] recently discovered that the lung microbial community is enriched by microbiota transferred from the intestine in patients with sepsis and ARDS. Interestingly, fecal microbiota transplantation (FMT) from normal mice can reduce acute lung injury by restoring intestinal microecology [76].
5 Intestinal Microbiota and Organ Dysfunction
LPS destroys the integrity of the gastrointestinal (GI) barrier, partly due to the weakening of bile components and altering mucosal hydrophobic properties. It can also cause gastric bleeding, bile acid reflux into the gastric cavity, and reduce bile salts in the ileum [77]. Phosphatidylcholine (PC) containing hydrophobic layer covers and protects the surface of the GI tract, contributing to the barrier's integrity. The integrity of the intestinal barrier is impaired in sepsis because of PC degradation [78]. Heparin-binding protein levels were associated with GI dysfunction in critically ill patients and positively correlated with sepsis [79]. Sepsis also induces high intestinal permeability and epithelial cell apoptosis. Preventing intestinal cell apoptosis can prevent intestinal barrier dysfunction [80]. A prospective clinical trial in 54 sepsis patients found that early enteral malnutrition can improve intestinal barrier function and inflammatory status [81].
Klebsiella pneumoniae infection leads to profound changes in the intestinal microbiome and metabolome. However, the intestinal microbiota and SCFAs could have a protective effect on lung injury [82]. The disturbed intestinal microbiota can directly contribute to organ dysfunction other than lung during sepsis. SCFAs derived from the gut microbiota can prevent acute kidney injury (AKI) [83]. The intestinal microbiota reaches the liver through the portal vein, promoting the capture and killing of circulating pathogens by Kupffer cells. However, antibiotic driven death of microbiota can lead to a failure in pathogen clearance and diffuse infection [84]. And microbiota has been also considered a key player in liver diseases by interacting with bile acid or inflammatory signals [85]. Cecal ligation and puncture mice receiving septic feces showed more severe liver inflammation and injury than receiving healthy feces [86]. It is fascinating that the gut microbiota can not only cause delirium indirectly through inflammatory pathways [87], but can also lead to acute brain dysfunction through bacterial translocation to the brain during sepsis [88]. However, FMT can reduce the harmful neurological effects [89].
6 Microbial-Specific Therapy in Sepsis
Studies [90, 91] have shown that probiotics may reduce the severity, duration, and incidence of respiratory infections in children, adults, and the elderly. Although the quality of the evidence in these meta-analyses was low, the heterogeneity of treatment effects between the studies was significant. However, the association between probiotic use in critically ill patients and infection risk remains to be verified [92].
FMT has been shown to have a clear or potential therapeutic effect in many diseases, such as in Clostridium difficile infection [93]. FMT enhances pathogen clearance by restoring host immunity and reversing the process of fatal sepsis, which is related to the proliferation of butyrate-producing Bacteroides [94]. A unified approach should be used in the selection of donors, preparation of fecal bacterial liquid, transplantation methods, and subsequent treatment. Standard clinical practice guidelines and high-quality clinical randomized controlled studies are needed to further verify its long-term safety.
Selective decontamination of the digestive tract (SDD) is the most controversial treatment method against pathogenic groups. SDD uses local antibiotics to suppress potential pathogens while maintaining colonization resistance [95]. A comprehensive network meta-analysis showed that SDD could prevent secondary infections and reduce overall mortality in critically ill patients [96]. However, in a clinical randomized controlled study conducted in 13 European ICUs, the use of SDD was not associated with a reduction in ICU-acquired bloodstream infections and mortality [97].
In recent years, the improvement of intestinal microbiota disorders by traditional Chinese medicine is also a hot spot in the treatment of sepsis. Jinzhi [98] and Xuan Bai Cheng Qi decoction (XBCQ) [99] can restore the damaged tight binding protein occludin of the intestinal epithelium and improve the intestinal barrier dysfunction. Studies have found that Chinese medicine, such as XBCQ [99], Qing Re Jie Du Fang Decoction (QRD) [100], Shenfu decoction (SFD) [101], and Jinzhi [98] could alleviate the intestinal flora disorders and have similar diversity and structure to the control group in sepsis. QRD [100], SFD [101], Jinzhi [98], and Sini decoction (SND) [102] also reduced the mortality rate and inflammatory cytokines in sepsis. As shown in supplementary material Table 1, we searched all articles related to sepsis and intestinal microbiota, and summarized the research progress of sepsis and intestinal microbiota.
7 Future Prospects
With the continuous in-depth study of the intestinal microecology in patients with sepsis, the role of intestinal microbiota in the development of sepsis will become clearer. Early identification of microbiota disorders as well as the restoration of the intestinal microbiota balance are expected to become important aspects for the treatment of sepsis.
8 Conclusion
Intestinal flora is essential for maintaining homeostasis in the host. Intestinal microbiota dysbiosis may be widespread and play a key role in the pathogenesis of sepsis, leading to organ dysfunction. Microbial targeted therapy has been shown to improve the prognosis of sepsis; however, large-scale studies are required to explore their safety and effectiveness.
Abbreviations
- SCFAs:
-
Short-chain fatty acids
- LOS:
-
Late onset sepsis
- ICU:
-
Intensive care unit
- IL:
-
Interleukin
- SGLT1:
-
Recombinant sodium/glucose cotransporter 1
- TLR:
-
Toll-like receptor
- TNF-α:
-
Tumor necrosis factor-α
- ARDS:
-
Acute respiratory distress syndrome
- FMT:
-
Fecal microbiota transplantation
- GI:
-
Gastrointestinal
- PC:
-
Phosphatidylcholine
- AKI:
-
Acute kidney injury
- SDD:
-
Selective decontamination of the digestive tract
- XBCQ:
-
Xuan Bai Cheng Qi decoction
- QRD:
-
Qing Re Jie Du Fang decoction
- SFD:
-
Shenfu decoction
- SND:
-
Sini decoction
References
Reinhart K, Daniels R, Kissoon N, et al. Recognizing Sepsis as a global health priority—a WHO resolution[J]. N Engl J Med. 2017;377(5):414–7.
Fleischmann-Struzek C, Mellhammar L, Rose N, et al. Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis[J]. Intensive Care Med. 2020;46(8):1552–62.
Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA. 2016;315(8):801–10.
Akash MSH, Fiayyaz F, Rehman K, et al. Gut microbiota and metabolic disorders: advances in therapeutic interventions[J]. Crit Rev Immunol. 2019;39(4):223–37.
Firmino FC, Porcellato D, Cox M, et al. Characterization of microbial communities in ethanol biorefineries[J]. J Ind Microbiol Biotechnol. 2020;47(2):183–95.
Ramakrishna BS. Role of the gut microbiota in human nutrition and metabolism[J]. J Gastroenterol Hepatol. 2013;28(Suppl 4):9–17.
Spanogiannopoulos P, Bess EN, Carmody RN, et al. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism[J]. Nat Rev Microbiol. 2016;14(5):273–87.
Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora[J]. Science. 2005;308(5728):1635–8.
Wang C, Li Q, Ren J. Microbiota-immune interaction in the pathogenesis of gut-derived infection[J]. Front Immunol. 1873;2019:10.
Gérard P. Gut microbiota and obesity[J]. Cell Mol Life Sci. 2016;73(1):147–62.
Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology[J]. EBioMedicine. 2020;51:102590.
Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: metabolism and perspective in obesity[J]. Gut Microbes. 2018;9(4):308–25.
Liu W, Cheng M, Li J, et al. Classification of the gut microbiota of patients in intensive care units during development of sepsis and septic shock[J]. Genom Proteom Bioinform. 2020;18(6):696–707.
Liu J, Wang M, Chen W, et al. Altered gut microbiota taxonomic compositions of patients with sepsis in a pediatric intensive care unit[J]. Front Pediatr. 2021;9:645060.
Dickson RP. The microbiome and critical illness[J]. Lancet Respir Med. 2016;4(1):59–72.
Klingensmith NJ, Coopersmith CM. The gut as the motor of multiple organ dysfunction in critical illness[J]. Crit Care Clin. 2016;32(2):203–12.
Bassetti M, Bandera A, Gori A. Therapeutic potential of the gut microbiota in the management of sepsis[J]. Crit Care. 2020;24(1):105.
Paone P, Cani PD. Mucus barrier, mucins and gut microbiota: the expected slimy partners?[J]. Gut. 2020;69(12):2232–43.
Bron PA, Kleerebezem M, Brummer RJ, et al. Can probiotics modulate human disease by impacting intestinal barrier function?[J]. Br J Nutr. 2017;117(1):93–107.
Sicard JF, Le Bihan G, Vogeleer P, et al. Interactions of intestinal bacteria with components of the intestinal mucus[J]. Front Cell Infect Microbiol. 2017;7:387.
Everard A, Belzer C, Geurts L, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity[J]. Proc Natl Acad Sci USA. 2013;110(22):9066–71.
Birchenough G, Schroeder BO, Bäckhed F, et al. Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier[J]. Gut Microbes. 2019;10(2):246–50.
Akrami K, Sweeney DA. The microbiome of the critically ill patient[J]. Curr Opin Crit Care. 2018;24(1):49–54.
Zaborin A, Smith D, Garfield K, et al. Membership and behavior of ultra-low-diversity pathogen communities present in the gut of humans during prolonged critical illness[J]. mBio. 2014;5(5):e01361-14.
Lankelma JM, Van Vught LA, Belzer C, et al. Critically ill patients demonstrate large interpersonal variation in intestinal microbiota dysregulation: a pilot study[J]. Intensive Care Med. 2017;43(1):59–68.
Wan YD, Zhu RX, Wu ZQ, et al. Gut microbiota disruption in septic shock patients: a pilot study[J]. Med Sci Monit. 2018;24:8639–46.
Wang C, Li Q, Tang C, et al. Characterization of the blood and neutrophil-specific microbiomes and exploration of potential bacterial biomarkers for sepsis in surgical patients[J]. Immun Inflamm Dis. 2021;9(4):1343–57.
Stewart CJ, Embleton ND, Marrs ECL, et al. Longitudinal development of the gut microbiome and metabolome in preterm neonates with late onset sepsis and healthy controls[J]. Microbiome. 2017;5(1):75.
Graspeuntner S, Waschina S, Künzel S, et al. Gut dysbiosis with bacilli dominance and accumulation of fermentation products precedes late-onset sepsis in preterm infants[J]. Clin Infect Dis. 2019;69(2):268–77.
Du B, Shen N, Tao Y, et al. Analysis of gut microbiota alteration and application as an auxiliary prognostic marker for sepsis in children: a pilot study[J]. Transl Pediatr. 2021;10(6):1647–57.
Lukovic E, Moitra VK, Freedberg DE. The microbiome: implications for perioperative and critical care[J]. Curr Opin Anaesthesiol. 2019;32(3):412–20.
Meckel KR, Kiraly DD. A potential role for the gut microbiome in substance use disorders[J]. Psychopharmacology. 2019;236(5):1513–30.
Wang F, Meng J, Zhang L, et al. Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model[J]. Sci Rep. 2018;8(1):3596.
Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units[J]. JAMA. 2009;302(21):2323–9.
Soares FS, Amaral FC, Silva NLC, et al. Antibiotic-induced pathobiont dissemination accelerates mortality in severe experimental pancreatitis[J]. Front Immunol. 1890;2017:8.
Deshpande A, Pasupuleti V, Thota P, et al. Risk factors for recurrent Clostridium difficile infection: a systematic review and meta-analysis[J]. Infect Control Hosp Epidemiol. 2015;36(4):452–60.
Song JH, Kim YS. Recurrent clostridium difficile infection: risk factors, treatment, and prevention[J]. Gut Liver. 2019;13(1):16–24.
Wu J, Gan T, Zhang Y, et al. The prophylactic effects of BIFICO on the antibiotic-induced gut dysbiosis and gut microbiota[J]. Gut Pathog. 2020;12:41.
Heneghan AF, Pierre JF, Tandee K, et al. Parenteral nutrition decreases paneth cell function and intestinal bactericidal activity while increasing susceptibility to bacterial enteroinvasion[J]. JPEN J Parenter Enteral Nutr. 2014;38(7):817–24.
Jirsova Z, Heczkova M, Dankova H, et al. The effect of butyrate-supplemented parenteral nutrition on intestinal defence mechanisms and the parenteral nutrition-induced shift in the gut microbiota in the rat model[J]. Biomed Res Int. 2019;2019:7084734.
Pierre JF. Gastrointestinal immune and microbiome changes during parenteral nutrition[J]. Am J Physiol Gastrointest Liver Physiol. 2017;312(3):G246-g256.
Ralls MW, Demehri FR, Feng Y, et al. Bacterial nutrient foraging in a mouse model of enteral nutrient deprivation: insight into the gut origin of sepsis[J]. Am J Physiol Gastrointest Liver Physiol. 2016;311(4):G734-g743.
Jia J, Xun P, Wang X, et al. Impact of postnatal antibiotics and parenteral nutrition on the gut microbiota in preterm infants during early life[J]. JPEN J Parenter Enteral Nutr. 2020;44(4):639–54.
Andersen S, Banks M, Bauer J. Nutrition support and the gastrointestinal microbiota: a systematic review[J]. J Acad Nutr Diet. 2020;120(9):1498–516.
Mcintyre MK, Winkler CJ, Gómez BI, et al. The effect of burn resuscitation volumes on the gut microbiome in a swine model[J]. Shock. 2020;54(3):368–76.
Yracheta J, Muraoka W, Wu X, et al. Whole blood resuscitation restores intestinal perfusion and influences gut microbiome diversity[J]. J Trauma Acute Care Surg. 2021;91(6):1002–9.
Yang R, Gallo DJ, Baust JJ, et al. Effect of hemorrhagic shock on gut barrier function and expression of stress-related genes in normal and gnotobiotic mice[J]. Am J Physiol Regul Integr Comp Physiol. 2002;283(5):R1263–74.
Muraoka WT, Granados JC, Gomez BI, et al. Burn resuscitation strategy influences the gut microbiota-liver axis in swine[J]. Sci Rep. 2020;10(1):15655.
Hammer KL, Stoessel A, Justo JA, et al. Association between chronic hemodialysis and bloodstream infections caused by chromosomally mediated AmpC-producing Enterobacteriaceae[J]. Am J Infect Control. 2016;44(12):1611–6.
Miao YY, Xu CM, Xia M, et al. Relationship between gut microbiota and phosphorus metabolism in hemodialysis patients: a preliminary exploration[J]. Chin Med J (Engl). 2018;131(23):2792–9.
Luo D, Zhao W, Lin Z, et al. The effects of hemodialysis and peritoneal dialysis on the gut microbiota of end-stage renal disease patients and the relationship between gut microbiota and patient prognoses[J]. Front Cell Infect Microbiol. 2021;11:579386.
Engelmann C, Adebayo D, Oria M, et al. Recombinant alkaline phosphatase prevents acute on chronic liver failure[J]. Sci Rep. 2020;10(1):389.
Defazio J, Fleming ID, Shakhsheer B, et al. The opposing forces of the intestinal microbiome and the emerging pathobiome[J]. Surg Clin North Am. 2014;94(6):1151–61.
Wu L, Holbrook C, Zaborina O, et al. Pseudomonas aeruginosa expresses a lethal virulence determinant, the PA-I lectin/adhesin, in the intestinal tract of a stressed host: the role of epithelia cell contact and molecules of the Quorum Sensing Signaling System[J]. Ann Surg. 2003;238(5):754–64.
Romanowski K, Zaborin A, Valuckaite V, et al. Candida albicans isolates from the gut of critically ill patients respond to phosphate limitation by expressing filaments and a lethal phenotype[J]. PLoS One. 2012;7(1):e30119.
Thaiss CA, Zmora N, Levy M, et al. The microbiome and innate immunity[J]. Nature. 2016;535(7610):65–74.
Maynard CL, Elson CO, Hatton RD, et al. Reciprocal interactions of the intestinal microbiota and immune system[J]. Nature. 2012;489(7415):231–41.
Haussner F, Chakraborty S, Halbgebauer R, et al. Challenge to the intestinal mucosa during sepsis[J]. Front Immunol. 2019;10:891.
Schiffrin EL. How structure, mechanics, and function of the vasculature contribute to blood pressure elevation in hypertension[J]. Can J Cardiol. 2020;36(5):648–58.
Pabst O. New concepts in the generation and functions of IgA[J]. Nat Rev Immunol. 2012;12(12):821–32.
Hrncir T, Stepankova R, Kozakova H, et al. Gut microbiota and lipopolysaccharide content of the diet influence development of regulatory T cells: studies in germ-free mice[J]. BMC Immunol. 2008;9:65.
Peterson CT, Sharma V, Elmén L, et al. Immune homeostasis, dysbiosis and therapeutic modulation of the gut microbiota[J]. Clin Exp Immunol. 2015;179(3):363–77.
Qin X, Caputo FJ, Xu DZ, et al. Hydrophobicity of mucosal surface and its relationship to gut barrier function[J]. Shock. 2008;29(3):372–6.
Bailón E, Cueto-Sola M, Utrilla P, et al. Butyrate in vitro immune-modulatory effects might be mediated through a proliferation-related induction of apoptosis[J]. Immunobiology. 2010;215(11):863–73.
Tordesillas L, Berin MC. Mechanisms of oral tolerance[J]. Clin Rev Allergy Immunol. 2018;55(2):107–17.
Ivanov I, Frutos RL, Manel N, et al. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine[J]. Cell Host Microbe. 2008;4(4):337–49.
Lee N, Kim WU. Microbiota in T-cell homeostasis and inflammatory diseases[J]. Exp Mol Med. 2017;49(5):e340.
Schaupp L, Muth S, Rogell L, et al. Microbiota-induced type I interferons instruct a poised basal state of dendritic cells[J]. Cell. 2020;181(5):1080-1096.e19.
Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease[J]. Nature. 2016;535(7610):75–84.
Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens[J]. Immunol Rev. 2017;279(1):90–105.
Choi H, Bae SJ, Choi G, et al. Ninjurin1 deficiency aggravates colitis development by promoting M1 macrophage polarization and inducing microbial imbalance[J]. Faseb j. 2020;34(6):8702–20.
Belizário JE, Faintuch J, Garay-Malpartida M. Gut Microbiome dysbiosis and immunometabolism: new frontiers for treatment of metabolic diseases[J]. Mediators Inflamm. 2018;2018:2037838.
Li KJ, Chen ZL, Huang Y, et al. Dysbiosis of lower respiratory tract microbiome are associated with inflammation and microbial function variety[J]. Respir Res. 2019;20(1):272.
Schuijt TJ, Lankelma JM, Scicluna BP, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia[J]. Gut. 2016;65(4):575–83.
Dickson RP, Singer BH, Newstead MW, et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome[J]. Nat Microbiol. 2016;1(10):16113.
Tang J, Xu L, Zeng Y, et al. Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-kB signaling pathway[J]. Int Immunopharmacol. 2021;91:107272.
Dial EJ, Romero JJ, Villa X, et al. Lipopolysaccharide-induced gastrointestinal injury in rats: role of surface hydrophobicity and bile salts[J]. Shock. 2002;17(1):77–80.
Zayat M, Lichtenberger LM, Dial EJ. Pathophysiology of LPS-induced gastrointestinal injury in the rat: role of secretory phospholipase A2[J]. Shock. 2008;30(2):206–11.
Sun JK, Shen X, Sun XP, et al. Heparin-binding protein as a biomarker of gastrointestinal dysfunction in critically ill patients: a retrospective cross-sectional study in China[J]. BMJ Open. 2020;10(7):e036396.
Otani S, Oami T, Yoseph BP, et al. Overexpression of BCL-2 in the intestinal epithelium prevents sepsis-induced gut barrier dysfunction via altering tight junction protein expression[J]. Shock. 2020;54(3):330–6.
Sun JK, Nie S, Chen YM, et al. Effects of permissive hypocaloric vs standard enteral feeding on gastrointestinal function and outcomes in sepsis[J]. World J Gastroenterol. 2021;27(29):4900–12.
Wu T, Xu F, Su C, et al. Alterations in the gut microbiome and cecal metabolome during klebsiella pneumoniae-induced pneumosepsis[J]. Front Immunol. 2020;11:1331.
Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut bacteria products prevent aki induced by ischemia-reperfusion[J]. J Am Soc Nephrol. 2015;26(8):1877–88.
Mcdonald B, Zucoloto AZ, Yu IL, et al. Programing of an intravascular immune firewall by the gut microbiota protects against pathogen dissemination during infection[J]. Cell Host Microbe. 2020;28(5):660-668.e4.
Adolph TE, Grander C, Moschen AR, et al. Liver-Microbiome axis in health and disease[J]. Trends Immunol. 2018;39(9):712–23.
Liu Z, Li N, Fang H, et al. Enteric dysbiosis is associated with sepsis in patients[J]. Faseb j. 2019;33(11):12299–310.
Zhang J, Bi JJ, Guo GJ, et al. Abnormal composition of gut microbiota contributes to delirium-like behaviors after abdominal surgery in mice[J]. CNS Neurosci Ther. 2019;25(6):685–96.
Singer BH, Dickson RP, Denstaedt SJ, et al. Bacterial dissemination to the brain in sepsis[J]. Am J Respir Crit Care Med. 2018;197(6):747–56.
Vendrik KEW, Ooijevaar RE, De Jong PRC, et al. Fecal microbiota transplantation in neurological disorders[J]. Front Cell Infect Microbiol. 2020;10:98.
Arumugam S, Lau CS, Chamberlain RS. Probiotics and synbiotics decrease postoperative sepsis in elective gastrointestinal surgical patients: a meta-analysis[J]. J Gastrointest Surg. 2016;20(6):1123–31.
Bo L, Li J, Tao T, et al. Probiotics for preventing ventilator-associated pneumonia[J]. Cochrane Database Syst Rev. 2014;10(10):Cd009066.
Suez J, Zmora N, Segal E, et al. The pros, cons, and many unknowns of probiotics[J]. Nat Med. 2019;25(5):716–29.
Wang JW, Kuo CH, Kuo FC, et al. Fecal microbiota transplantation: Review and update[J]. J Formos Med Assoc. 2019;118(Suppl 1):S23-s31.
Kim SM, Defazio JR, Hyoju SK, et al. Fecal microbiota transplant rescues mice from human pathogen mediated sepsis by restoring systemic immunity[J]. Nat Commun. 2020;11(1):2354.
Donnelly JP. Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis[J]. J Antimicrob Chemother. 1993;31(6):813–29.
Price R, Maclennan G, Glen J. Selective digestive or oropharyngeal decontamination and topical oropharyngeal chlorhexidine for prevention of death in general intensive care: systematic review and network meta-analysis[J]. BMJ. 2014;348:g2197.
Wittekamp BH, Plantinga NL, Cooper BS, et al. Decontamination strategies and bloodstream infections with antibiotic-resistant microorganisms in ventilated patients: a randomized clinical trial[J]. JAMA. 2018;320(20):2087–98.
Xu J, Song J, Zhang Y, et al. Jinzhi protects lipopolysaccharide-treated mice against mortality by repairing intestinal mucosal barrier damage and intestinal microecology[J]. Biomed Pharmacother. 2020;123:109749.
Mu S, Zhang J, Du S, et al. Gut microbiota modulation and anti-inflammatory properties of Xuanbai Chengqi decoction in septic rats[J]. J Ethnopharmacol. 2021;267:113534.
Cao H, Zong C, Dai W, et al. The effects of chinese medicine QRD, antibiotics, and probiotics on therapy and gut microbiota in septic rats[J]. Front Cell Infect Microbiol. 2021;11:712028.
Liu J, Liu F, Liang T, et al. Efficacy of Shenfu decoction on sepsis in rats with condition induced by cecal ligation and puncture[J]. J Tradit Chin Med. 2020;40(4):621–8.
Wang W, Chen Q, Yang X, et al. Sini decoction ameliorates interrelated lung injury in septic mice by modulating the composition of gut microbiota[J]. Microb Pathog. 2020;140:103956.
Acknowledgements
We would like to thank the Master Yuqing Cui for consulting related literature and Master Mengxing Peng for the diagram.
Funding
This study was supported by the United Fund of National Natural Science Foundation of China (Grant No. U2004110), the National Natural Science Foundation of China (Grant No. 82172129); The study of mechanism of Gabexate Mesilate in the treatment of sepsis and septic shock (Grant No. 2019-hx-45).
Author information
Authors and Affiliations
Contributions
All the authors contributed substantially to the work presented in this article. TWS conceived of the study. LXW and HBZ revised the article. All authors have approved the final and submitted version of the manuscript.
Corresponding authors
Ethics declarations
Conflict of Interest
The authors have no conflicts of interest to disclose.
Ethical Approval
Not applicable.
Consent to Participate
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visithttp://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sun, T., Wang, L. & Zhang, H. Intestinal Microbiota in Sepsis. Intensive Care Res 2, 1–7 (2022). https://doi.org/10.1007/s44231-022-00001-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s44231-022-00001-8